)
)
)
HiFiBiO Therapeutics
HiFiBiO is a clinical-stage biotherapeutics company advancing a pipeline of First-in-Class and Best-in-Class antibody therapeutics to treat advanced R&R cancer and autoimmune (I&I) disease.
. *We will not be meeting with CROs/CMOs
I&I Pipeline:
- HFB200604 - Superior BTLA Agonist for Th1/Th17 diseases (IND Cleared)
- HFB100204 - CXCR5 Depletor (B cells and Tfh cells) that inhibits CXCL13 migration
- HFB302401 - Bi-paratopic KLRG1 depletor (cytotoxic CD8+ T cells)
- HFB202501 - Enhanced PD1 Depletor (mono and bispecific)
- HFB2027 - TNFR2 Agonist (mono and bispecific)
IO Pipeline:
- HFB200603 - BTLA Antagonist for 3L MSS-CRC+Liver Mets and 3L ccRCC (Phase 1)
- HFB200301 / Emunkitug - TNFR2 Agonist for 3L NSCLC (Phase 1)
- HFB200902 - Gal-9 Antagonist for Advanced Solid Tumors (IND Cleared)
- HFB10110 - CCR8 Depletor for Advanced Solid Tumors
- HFB3022 - DDR1 Blocker/Depletor (Internalizing Abs) disrupts collagen formation
Address
CambridgeMassachusetts
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)